Kyäni Launches First-of-Its-Kind Electrolyte Drink Mix

Kyäni, Inc., an internationally recognized health and wellness company, just announced the launch of Kyäni Electo™— a first-of-its-kind electrolyte drink mix that features a combination of electrolyte minerals to support hydration, and a proprietary NR-8™ polyphenol blend to support nitric oxide regeneration.

Nitric oxide—a vasodilator that allows for increased circulation and the delivery of oxygen and nutrients to the muscles and tissue—is the foundation for all Kyäni products. NR-8 works by protecting an enzyme needed to generate nitric oxide.

Available in two crave-worthy flavors, Coconut Lime and Crisp Apple, Electro is the perfect go-to hydration source that:

Supports proper muscle contraction (including the heart)
Promotes balanced pH
Helps support healthy blood pressure
Helps manage cellular fluid balance
Supports nitric oxide production
Supports exercise endurance

With this new product, Kyäni is empowering its Business Partners with the opportunity to substantially increase their businesses. According to the lay press, 75% of Americans are chronically dehydrated. This growing health concern creates a vast marketplace for hydration products. The Electrolyte drinks market is forecast to significantly rise in spending on functional food & beverages in the coming years. The Global Electrolyte Drinks Market size was valued at USD 20.7 Bn in 2020 and is expected to reach USD 31.0 Bn by 2027, with a growing CAGR of 6.1% during the forecast period.

“Electro is the only hydration support formula on the market that features a nitric oxide regeneration blend. It isn’t just for people who are athletes or who do sports. In a world where 75% of us are dehydrated, this is a daily use product for everyone.” — Mark Macdonald, International bestselling author and Co-creator of the Nitro Nutrition program.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”